<DOC>
	<DOCNO>NCT00645190</DOCNO>
	<brief_summary>The purpose randomize , double-blind , active-controlled , flexible dosage , multicenter study evaluate effectiveness safety galantamine tablet ( 16-24mg/day ) 16 week treatment mild moderate Alzheimer 's Disease ( AD ) compare Donepezil .</brief_summary>
	<brief_title>A Randomized , Double-blind , Flexible Dose , Multicenter Study Evaluate Effectiveness Safety Galantamine IR Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>This randomize , double-blind , active-controlled , flexible dosage , multicenter study evaluate effectiveness safety galantamine tablet treatment mild moderate AD . The comparator Donepezil tablet . At least 206 patient randomize study . The study consist 3 phase : screening phase , single-blind run-in phase double-blind treatment phase . Screening phase le 2 week eligible assessment ; If patient take anti-dementia drug screening , he/she stop drug enter single-blind run-in phase . The patient take anti-dementia drug enter baseline directly . During single-blind run-in phase , eligible patient take placebo twice daily 4 week . Double-blind treatment phase 16 week . At baseline , patient still eligible inclusion/exclusion criterion randomize either galantamine group donepezil group 1:1 ratio , drug take twice daily flexible dose 16 week . Dose titrate first 9-12 week . Dose fix 16mg/day 24mg/day base tolerability patient judge investigator . The primary effectiveness endpoint change ADAS-cog/11 week 16 baseline , secondary endpoint responder rate term ADAS-cog/11 . Safety evaluation include adverse event , physical examination , ECG , safety laboratory test . Study drug take orally twice day . The treatment duration 16 week . Initial galantamine dose 8 mg/day , dose increase 16mg/day week 5 24 mg/day week 9 . At week 12 , dose fix either 16mg/day 24mg/day discretion investigator . Initial donepezil dose 5mg/day , dose increase 10mg/day week 9 . At week 12 , dose fix either 5mg/day 10mg/day discretion investigator .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Outpatients diagnose mild moderate probable AD . The diagnosis establish accordance classification probable AD NINCDSADRDA MMSE score 1024 ( inclusive ) screen Patients live regular daily visit responsible caregiver .Has sign informed consent form subject assent form caregiver Patients neurodegenerative disorder Parkinson 's disease Patients condition possibly result cognitive impairment , e.g . acute cerebral trauma , infection Has evidence multiinfarct dementia clinically active cerebrovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Alzheimer Disease</keyword>
	<keyword>galantamine</keyword>
</DOC>